IL-2Rα is a Potential Biomarker for Heart Failure Diagnosis of Patients with End-Stage Renal Disease and Haemodialysis
Authors' conclusion
This study underscores the potential of IL-2Rα as a valuable biomarker for HF diagnosis and management in haemodialysis patients with ESRD and contributes to our understanding of this high-risk population.
Study context
- Population
- Patients with end-stage renal disease undergoing haemodialysis, Second Hospital of Tianjin Medical University
- Participants
- 68 patients
- Comparison
- Plasma cytokines as heart failure (HF) biomarkers vs sST2 and N-terminal pro-brain natriuretic peptide (NT-proBNP)
- Outcome
- Diagnosis of HFrEF by plasma cytokines (ROC analysis)
Methodological detailssingle-centre
- Single-centre
Performance
As reported in the abstract
Prediction of HFrEF (ROC)
| Test or model | AUC | OR |
|---|---|---|
| TNF-α | 0.85 | 1.080 (95% CI 1.033-1.128, P = 0.001) |
| IFN-γ | 0.84 | 1.836 (95% CI 1.289-2.615, P = 0.003) |
| IL-2Rα | 0.82 | 1.022 (95% CI 1.009-1.035, P = 0.001) |
AUC
TNF-α0.85
IFN-γ0.84
IL-2Rα0.82
OR
TNF-α1.080 (95% CI 1.033-1.128, P = 0.001)
IFN-γ1.836 (95% CI 1.289-2.615, P = 0.003)
IL-2Rα1.022 (95% CI 1.009-1.035, P = 0.001)
- SCGF-β, CXCL10, IL-1α, IL-6, IL-8, IL-16, IL-1Ra, IFN-γ, TNF-α, leukaemia inhibitory factor (LIF), CCL3, IL-10, IL-2Rα, TNFSF10, macrophage colony-stimulating factor (M-CSF), granulocyte colony-stimulating factor (G-CSF) and stem cell factor (SCF) significantly increased, CCL11/eotaxin decreased in HF with reduced ejection fraction (HFrEF) vs control
- P < 0.05
Further findings
All-cause mortality · median follow-up 14 months
| HR (95% CI) | P value | ||
|---|---|---|---|
| IL-2Rα (plasma)Multivariate Cox, adjusted | 1.010 (1.001–1.020) | P = 0.039 | |
| 0.512Hazard ratio (log scale) |
| Outcome | Values |
|---|---|
| HF with LVEF <50% vs controls | IL-2Rα AUC 0.77 · OR 1.018 (95% CI 1.007-1.030, P = 0.001) |
| HF severity | TNF-α AUC 0.89 · OR 1.140 (95% CI 1.039-1.250, P = 0.005) |
| RV systolic dysfunction | IL-2Rα AUC 0.80 · OR 1.017 (95% CI 1.007-1.027, P = 0.001) |
- All-cause mortality — Patients with all-cause mortality
- 10 (14.7%)
Original publication
IL-2Rα is a Potential Biomarker for Heart Failure Diagnosis of Patients with End-Stage Renal Disease and Haemodialysis. ESC Heart Fail. Published 12 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →